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Biomaterials for antimalarial drug transport still need to be investigated in order to attain nanocarriers that
can tackle essential issues related to malaria treatment, e.g. complying with size requirements and target-
ing specificity for their entry into Plasmodium-infected red blood cells (pRBCs), and limiting premature
drug elimination or drug resistance evolution. Two types of dendritic macromolecule that can form
vehicles suitable for antimalarial drug transport are herein explored. A new hybrid dendritic-linear-dendri-
tic block copolymer based on Pluronic® F127 and amino terminated 2,2’-bis(glycyloxymethyl)propionic
acid dendrons with a poly(ester amide) skeleton (HDLDBC-bGMPA) and an amino terminated dendro-
nized hyperbranched polymer with a polyester skeleton derived from 2,2’-bis(hydroxymethyl)propionic
acid (DHP-bMPA) have provided self-assembled and unimolecular micelles. Both types of micelle carrier
are biocompatible and exhibit appropriate sizes to enter into pRBCs. Targeting studies have revealed
different behaviors for each nanocarrier that may open new perspectives for antimalarial therapeutic
approaches. Whereas DHP-bMPA exhibits a clear targeting specificity for pRBCs, HDLDBC-bGMPA is
incorporated by all erythrocytes. It has also been observed that DHP-bMPA and HDLDBC-bGMPA incor-
porate into human umbilical vein endothelial cells with different subcellular localization, i.e. cytosolic and
nuclear, respectively. Drug loading capacity and encapsulation efficiencies for the antimalarial com-
pounds chloroquine, primaquine and quinacrine ranging from 30% to 60% have been determined for
both carriers. The resulting drug-loaded nanocarriers have been tested for their capacity to inhibit
Plasmodium growth in in vitro and in vivo assays.
Introduction
According to the latest estimates, around 219 million cases of
malaria occurred globally in 2017 and the disease led to
435 000 deaths.1 People living in the poorest countries are the
most vulnerable, with approximately 90% of deaths in Africa,
of which 70% are children under 5 years of age. Although
increased prevention and control measures have led to a
reduction in malaria mortality rates by more than 42% globally
since 2000, an estimated 3.4 billion people are still at risk of
being infected and developing disease. Despite the undeniable
importance of malaria elimination on the global research
agenda, current vaccines in development do not offer pro-
spects of complete protection2 and the available front-line
drugs are rapidly losing efficacy, with resistance already
evolved to the first-line drug artemisinin.3 As a result, since
2014 the malaria incidence and mortality decline have stalled.
Thus, alternative strategies4 working through radically new
mechanisms are urgently needed. Antimalarial drugs can
potentially target a suite of pathogen life stages inside two
different hosts: humans and the insect vector. Infection starts
when a parasitized female Anopheles mosquito, while taking a
blood meal, inoculates sporozoites of the malaria parasite, the
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protist Plasmodium spp. In the liver, sporozoites develop into
merozoites,5 which enter the circulation, invade red blood
cells (RBCs)6 and replicate asexually through ring, trophozoite
and schizont stages to produce daughter cells that invade new
RBCs to perpetuate the blood-stage cycle. Some parasites even-
tually differentiate into sexual stages, female or male gameto-
cytes that are ingested by a mosquito from peripheral blood.
Following fertilization in the insect’s midgut, the zygote differ-
entiates into an ookinete that moves through the midgut epi-
thelium and forms an oocyst, which releases sporozoites. The
malaria transmission cycle is restarted when sporozoites
migrate to the salivary glands and are injected into a human
with the mosquito’s next bite.
Most chemotherapeutic approaches against malaria are tar-
geted at the asexual, blood-stage parasites that are responsible
for all symptoms and pathologies of the disease.7 Currently
administered antimalarial drugs are in free form in the blood
circulation and have poor specificity for Plasmodium-infected
RBCs (pRBCs). This incurs the risk of having to deliver large
overall doses over an extended period of time to compensate
for drug removal through spleen and liver clearance and
kidney filtration. However, patient non-compliance and low
concentration thresholds to ward off potential side effects
often end up in sublethal local drug amounts reaching
infected cells, which in turn stimulate resistance evolution.
Because malaria pathophysiology is so complex and the
disease is so widespread, it is generally accepted that to
achieve eradication a combination of weapons will be needed.8
These include the improvement of existing approaches and the
development of new ones,9 with drug therapy remaining the
mainstay of treatment and prevention,10 and nanotechnology
being able to provide innovative useful tools.11 The objective of
delivering drugs exclusively to a selected site with minimal
exposure for sensitive adjacent healthy cells or tissues is the
holy grail of the fast-developing nanomedicine field.12
Encapsulation of drugs in targeted nanovectors is a rapidly
growing area with a clear applicability to infectious disease
treatment,13 and pharmaceutical nanotechnology has been
identified as a potentially essential asset to the future fight
against malaria.14,15
In the search for suitable nanocarriers for the treatment of
infectious diseases, dendrimers stand out as valuable candi-
dates due to their inherent features for building nanostructures
with controlled size, morphology and surface functionali-
zation.16 In a previous work we had explored different amphi-
philic cationic dendritic derivatives based on 2,2′-bis(hydroxy-
methyl)propionic acid (bis-MPA)17 as nanocarriers for the tar-
geted delivery of antimalarial drugs.18 These dendritic deriva-
tives consisted of Janus dendrimers19 or hybrid dendritic-
linear-dendritic block copolymers (HDLDBC),20 and both self-
assembled into micelles with glycine groups at the surface.
Although some of these structures exhibited specific pRBC tar-
geting and in vitro antimalarial activity, they had an excessive
unspecific toxicity, a very large size after antimalarial drug
loading (>150 nm), and their in vivo tests had been
preliminary.
Here we build on our previous work to explore new specifi-
cally targeted delivery systems for antimalarial drugs of a size
after drug encapsulation (<30 nm) sufficiently small to facili-
tate their entry into pRBCs.21 Accordingly, two types of cationic
dendritic derivative are proposed, which mainly differ in the
way they form the nanocarrier, either self-assembled micelles
or unimolecular micelles. As for the former, and on the basis
of the promising results shown by the previously reported
Pluronic® F127 HDLDBC derivative that contained polyester
dendrons,18 we have herein conjugated Pluronic® F127 with
poly(ester amide) dendrons to generate a new micelle-forming
self-assembling amphiphilic cationic HDLDBC (Fig. 1A). The
combination of the hydrolytic degradability of ester linkages
and the stability and H-bond-forming ability of amide groups
has proven very interesting for the design of synthetic poly-
mers for biomedical applications.22,23 Accordingly, a poly(ester
amide) dendron conjugated at both ends of Pluronic®
F127 has been herein envisaged as a possibility to modulate
the size and stability of self-assembled micelles given the
additional H-bonding interactions due to amide groups. The
dendron employed derives from the monomer 2,2′-bis(glycy-
loxymethyl)propionic acid (bis-GMPA), which was recently
described by us as one of the few examples of poly(ester
amide) dendritic structures reported in the literature, which
showed high potential for biomedical applications due to the
biocompatibility, degradability and positive results in drug
and gene delivery of its dendritic derivatives.24 As for the
achievement of a unimolecular micelle carrier, we have
Fig. 1 Chemical structure and cartoon representation of (A) micelle
formation by HDLDBC-bGMPA, a hybrid dendritic-linear-dendritic block
copolymer composed by Pluronic F127 and dendrons derived from 2,2’-
bis(glycyloxymethyl)propionic acid (bis-GMPA), and (B) DHP-bMPA, den-
dronized hyperbranched polymers derived from 2,2’-bis(hydroxymethyl)
propionic acid (bis-MPA) hyperbranched polymers and bis-MPA den-
drons functionalized with glycine groups.
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selected dendronized hyperbranched polymers (DHPs), also
called pseudo-dendrimers, based on a hyperbranched polymer
of bis-MPA, conjugated at its periphery with bis-MPA dendrons
with exposed glycine moieties (Fig. 1B). We demonstrated that
these DHP-bMPA derivatives could deliver DNA into mesenchy-
mal cells.25 However, their potential as drug carriers remains
to be explored. In this respect, these polymers showed appro-
priate biocompatibility and degradability that make them
interesting to be investigated as carriers for antimalarial drug
delivery.
Both types of structure have been investigated for their tar-
geting towards pRBCs, and the drug loading capacity and
encapsulation efficiencies of the carriers have been tested with
the antimalarial compounds chloroquine (CQ), primaquine
(PQ) and quinacrine (QN). The resulting nanocarriers have
been assayed for their capacity to inhibit Plasmodium growth
in in vitro and in vivo assays.
Materials and methods
Reagents
Unless otherwise indicated, all reagents were purchased from
Sigma-Aldrich® or Acros™, and used always without further
purification. Dichloromethane (DCM) and tetrahydrofuran
(THF) were dried using solvent purification systems.
Synthesis and characterization of the dendritic derivatives
Globular DHP-bMPA dendronized hyperbranched polymers as
well as DHP-bMPA-Rho, a DHP containing covalently linked
rhodamine B fluorophore, were synthesized as previously
reported by us.25 HDLDBC-bGMPA was prepared by copper
azide–alkyne cycloaddition (CuAAC) coupling of the t-Boc pro-
tected bis-GMPA dendron and the Pluronic® F127 bis(alkyne)
derivative as depicted in Fig. 2A.
Fig. 2 Synthesis of HDLDBC-bGMPA (A) and chemical characterization by 1H NMR (B), 13C NMR (C), FTIR (D) and SEC (E). 1H NMR spectra with
signal relative integration, the 1H–1H COSY NMR spectra and full 13C NMR spectra of HDLDBC-bGMPA are gathered in the ESI.†
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Synthetic procedure and analytical data of t-Boc protected
HDLDBC-bGMPA. Alkyne functionalized Pluronic® F127
(1.00 g, 7.74 × 10−2 mmol, 1.00 eq.) and bis-GMPA dendron
(NHBoc)8 (514 mg, 2.01 × 10
−1 mmol, 2.60 eq.) were dissolved
into 8 mL of dimethylformamide (DMF) in a Schlenk flask and
3 vacuum–argon cycles were made to remove the air. The reac-
tion mixture was stirred under argon atmosphere at 45 °C.
CuSO4·5H2O (18.2 mg, 6.19 × 10
−2 mmol, 0.80 eq.), (L)-ascor-
bate (24.1 mg, 1.24 × 10−1 mmol, 1.60 eq.) and tris[(1-benzyl-
1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 32.8 mg, 6.19 × 10−2
mmol, 0.80 eq.) were dissolved into DMF (4 mL) in a second
Schlenk flask and exposed to 3 vacuum–argon cycles. The
copper solution was stirred under argon atmosphere at 45 °C
for 15 min and was added through a cannula to the previous
azide–alkyne reaction. The resulting mixture was stirred
under argon atmosphere at 45 °C for 2 days. Then, hot brine
(100 mL) was added to the reaction mixture and the product
was extracted with dichloromethane (3 × 100 mL). The organic
phases were collected, washed with hot brine (2 × 100 mL),
dried over anhydrous MgSO4 and the solvent was evaporated
under reduced pressure to obtain a yellow solid. The crude
product was precipitated into cold diethyl ether, recovered by
filtration and washed with cold diethyl ether to yield a white
powder. Finally, the product was dialyzed (cellulose mem-
brane, 1000 Da cut-off, Spectra/Por®) against methanol for
24 h to obtain a light yellow solid (855 mg, 61%). 1H NMR
(400 MHz, CDCl3) δ (ppm): 1.11 (m, 201H), 1.26 (m, 42H), 1.41
(m, 152H), 1.62 (m, 4H), 1.94 (m, 4H), 3.38 (m, 67H), 3.44–3.74
(m, ∼1000H), 3.81 (t, J = 4.8 Hz, 4H), 3.88 (m, 32H), 3.94 (m,
8H), 3.88 (m, 16H), 4.11 (t, J = 6.4 Hz, 4H), 4.18–4.35 (m, 60H),
4.43 (t, J = 4.8 Hz, 4H) 5.29 (s, 4H), 5.35 (bs), 7.02 (d, J = 8.8 Hz,
4H), 7.17 (bs), 7.82 (s, 2H), 8.00 (d, J = 8.0 Hz, 4H). FTIR
(νmax/cm
−1): 3360 (N–H st), 2883 (C–H st), 1755 (CvO st ester),
1718 (CvO st carbamate), 1670 (CvO st amide), 1533 (N–H δ),
1468 (CH2, –CH3 δ), 1101 (C–O–C st). SEC (ref PMMA): 2 popu-
lations; Mw 19 745 g mol
−1; Đ: 1.08.
Cleavage of t-Boc protecting groups and analytical data of
HDLDBC-bGMPA. t-Boc protected HDLDBC-bGMPA (653 mg,
3.62 × 10−2 mmol, 1.00 eq.) was dissolved into ethyl acetate
(3 mL), and a saturated solution of HCl(g) (7 mL) in ethyl
acetate was carefully added to it. The reaction was stirred at
room temperature for 45 min until a white gel appeared. The
mixture was diluted with ethyl acetate (40 mL) and was stirred
for an additional 30 min. Then, it was stirred under vacuum to
remove the hydrochloric acid and the solvent was evaporated
under reduced pressure. The gel was washed first with pure
ethyl acetate and subsequently with pure methanol. In each
case, the solution was stirred for 15 min under vacuum in
order to remove the residual hydrochloric acid traces and then,
the solvent was evaporated under reduced pressure to obtain
a solid (615 mg, quantitative). 1H NMR (500 MHz, CD3OD)
δ (ppm): 1.14 (m, 201H), 1.27 (s, 6H), 1.32 (s, 20H), 1.39 (s,
24H), 1.64 (m, 4H), 1.95 (m, 4H), 3.47 (m, 67H), 3.51–3.73 (m,
∼1000H), 3.84 (t, J = 4.8 Hz, 4H), 3.96 (s, 8H), 4.00 (s, 16H),
4.03 (s, 32H), 4.12 (t, J = 6.0 Hz, 4H), 4.31 (m, 24H), 4.45 (m,
40H) 5.30 (s, 4H), 7.38 (d, J = 8.8 Hz, 4H), 8.23 (d, J = 8.8 Hz,
4H), 8.19 (s, 2H). 13C NMR (125 MHz, CD3OD) δ (ppm):
17.4–18.3, 26.3, 26.9, 29.3, 31.1, 41.5, 42.2, 47.3, 51.3,
62.6–76.8, 115.9, 124.2, 125.8, 132.8, 140.4, 163.7, 167.6, 168.8,
170.8–171.2, 174.0, 174.7–175.0. FTIR (νmax/cm
−1): 3600–3300
(bs N–H+), 2885 (C–H st), 1751 (CvO st ester), 1663 (CvO st
amide and N–H+ δ), 1545 (N–H δ), 1468 (CH2–, CH3 δ), 1099
(C–O–C st).
Characterization techniques. 1H and 13C Nuclear Magnetic
Resonance (NMR) experiments were performed using a Bruker
AV-400 (1H: 400 MHz, 13C: 100 MHz) or a Bruker AV-500 (1H:
500 MHz, 13C: 125 MHz) spectrometer (Bruker Corporation,
Billerica, MA, USA), employing as solvents deuterated chloro-
form (CDCl3), deuterated methanol (CD3OD) or deuterated
dimethyl sulfoxide ((CD3)2SO). The chemical shifts are inid-
cated in ppm relative to tetramethylsilane (TMS) and the coup-
ling constant in Hz; the solvent residual peak was used as
internal standard for spectrum calibration. Fourier trans-
formed infrared (FTIR) spectroscopy was performed using a
Bruker Vertex 70 spectrophotometer in ATR (attenuated total
reflectance) mode and recorded between 4000 and 800 cm−1.
Size exclusion chromatography (SEC) was performed with a
Walter e2695 Alliance employing two in series HR4 and HR1
Styragel columns (500 and 104 Å of pore size, respectively) and
a Waters 2424 evaporation light scattering detector with a
sample concentration of 1 mg mL−1 in THF (HPLC grade) with
a flow rate of 1 mL min−1 at 35 °C; poly(methyl methacrylate),
PMMA, was used as standard for calibration.
Self-assembly of HDLDBC-bGMPA
HDLDBC-bGMPA was mixed with the corresponding amount
of distilled water and cooled down to 4 °C for 30 min until
complete dissolution. Then, the solution was slowly heated to
room temperature to trigger the formation of the water soluble
nanocarriers. The critical micelle concentration (CMC) was
determined using the Nile Red technique.26 Briefly, 2 mL of
distilled water solutions of HDLDBC-bGMPA with concen-
trations ranging from 0.1 to 5 mg mL−1 were prepared at
25 °C. Nile Red was dissolved in ethanol at a concentration of
0.25 mM and 10 µL of this solution was added to each sample.
The mixtures were then stirred at room temperature for 1 h in
the dark with an orbital shaker. The fluorescence emission
spectrum of each solution was recorded with a PerkinElmer LS
55 fluorimeter after excitation at λex = 550 nm.
Preparation of carrier-antimalarial drug conjugates and drug
release assays
The antimalarial compounds CQ, PQ and QN were encapsu-
lated within the corresponding carrier (DHP-bMPA or
HDLDBC-bGMPA) following the oil-in-water procedure pre-
viously employed by us for CQ and PQ.18 Briefly, each dendritic
derivative and the corresponding drug were dissolved into a
mixture of DCM and distilled water (1 : 1) at feeding ratios of
wDHP : wdrug = 1 : 0.5 and wHDLDBC : wdrug = 1 : 1. The samples
were vigorously stirred at room temperature employing an
orbital shaker under ventilation until complete evaporation of
DCM (around 2 h). Non-encapsulated drug was removed by
Paper Biomaterials Science
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dialysis (regenerated cellulose membrane, MW 1000 Da cut
off, Spectra/Por®) against distilled water (200 mL) at 4 °C for
16 h. The amount of encapsulated drug was indirectly deter-
mined: the quantity of drug present in the dialysis water was
measured by UV-VIS spectrometry (Varian Cary50 Probe UV-
visible spectrophotometer) at the wavelengths of λA(CQ) =
345 nm for CQ, λA(PQ) = 259 nm for PQ and λA(QN) = 280 nm for
QN and was subtracted from the initially incorporated drug.
The samples were freeze-dried with a Telstar Cryodos 50
freeze-dryer in order to increase their stability over long
storage periods.
The release of CQ encapsulated within HDLDBC-bGMPA
and DHP-bMPA was studied by dialysis against phosphate
buffered saline (PBS). 2 mL of the dendrimer/drug conjugates
were dialyzed against 200 mL of PBS (regenerated cellulose
dialysis membrane, MW 1000 Da cut-off, Spectra/Por®) under
stirring at 37 °C. For CQ determination, aliquots (2 mL) were
withdrawn at different times from the waters of dialysis up to
72 h (specifically at 0, 2, 4, 6, 24, 48, and 72 h). An identical
procedure was performed with a control solution of free CQ at
the same concentration as in the conjugate preparation.
Fluorescent labeling of HDLDBC-bGMPA
HDLDBC-bGMPA nanocarriers were labeled by encapsulating a
low water soluble modified rhodamine B (Rho(C17)2) red
fluorophore previously reported by us,27 and the oil-in-water
procedure was employed to encapsulate the fluorophore within
the nanocarrier. The selected feeding ratio in this case was
(1 : 0.15) (wHDLDBC : wRho). The release profile of Rho(C17)2
from the dendrimer/Rho(C17)2 conjugates was studied by
dialysis similarly as the drug release procedure described
above. In this case, 2 mL of the HDLDBC-bGMPA/Rho(C17)2
conjugate containing 0.15 mg mL−1 of encapsulated Rho(C17)2
were dialyzed (regenerated cellulose membrane, MW 2000 Da
cut off, Spectra/Por®) against distilled water (200 mL) at 37 °C.
At different times up to 72 h, 2 mL aliquots were withdrawn
from where the quantity of Rho(C17)2 was determined by
measuring fluorescence intensity (λex = 540 nm, λem = 580 nm).
Transmission electron microscopy (TEM) and atomic force
microscopy (AFM) analysis
TEM images were obtained with a FEI TECNAI T20 electron
microscope (FEI Company, Eindhoven, The Netherlands) with
200 kV beam power, using holey carbon film 300 mesh cop-
pered grids (Agar Scientific Ltd). A droplet of an aqueous solu-
tion of the sample at a concentration of 1 mg mL−1 was de-
posited on the grid and let to adsorb for 30 s, removing the
excess aqueous solution by blotting with filter paper. A droplet
of a 3% w/v aqueous solution of phosphotungstic acid used as
negative stain was deposited on the grid and left for 10 s
before removing the excess staining solution by blotting with
filter paper. The grid was dried for at least 24 h under atmos-
pheric pressure at room temperature. The average size of the
different nanocarriers was obtained by analysing ≥100 struc-
tures in ≥4 TEM images.
For AFM analyses, 10 μL of 1 μg mL−1 or 10 ng mL−1 dendri-
mer solution in double deionised water (ddH2O; MilliQ
system, Millipore) were deposited on cleaved mica substrates
and, after an adsorption time of about 5 min, 40 μL ddH2O
were added. High-resolution images were obtained with a
MultiMode 8 atomic force microscope equipped with a
NanoScope V controller (Bruker Corporation) operating in
ScanAsyst mode in liquid, using ScanAsyst-Fluid + probes
(Bruker Corporation).
Plasmodium falciparum cell culture and parasite growth
inhibition assay
P. falciparum 3D7 was grown in vitro in human RBCs of blood
group type B prepared as described elsewhere28 using pre-
viously established conditions.29 Briefly, parasites (thawed
from glycerol stocks) were cultured at 37 °C in T25 flasks (SPL
Life Sciences) containing RBCs in Roswell Park Memorial
Institute (RPMI) complete medium (supplemented with 5 g
L−1 Albumax II and 2 mM glutamine) under a gas mixture of
92% N2, 5% CO2, and 3% O2. Synchronized ring stage cultures
were obtained by 5% sorbitol lysis and synchronized late stage
cultures were obtained using 70% Percoll® (GE Healthcare)
purification to enrich in late trophozoites and early schi-
zonts;30 the medium was changed every 2 days maintaining
3% hematocrit. For culture maintenance, parasitemias were
kept below 5% late forms by dilution with fresh RBCs. The
human blood used in this work was commercially obtained
from the Banc de Sang i Teixits (http://www.bancsang.net).
Blood was not specifically collected for this research; the pur-
chased units had been discarded for transfusion, usually
because of an excess of blood relative to anticoagulant solu-
tion. Prior to their use, blood units underwent the analytical
checks specified in the current legislation. Before being deli-
vered to us, unit data were anonymized and irreversibly disso-
ciated, and any identification tag or label had been removed in
order to guarantee the non-identification of the blood donor.
No blood data were or will be supplied, in accordance with the
current Ley Orgánica de Protección de Datos and Ley de
Investigación Biomédica. The blood samples will not be used
for studies other than those made explicit in this research.
Experiments were approved by the Ethics Committee of the
Hospital Clínic de Barcelona.
To isolate P. falciparum merozoites, a 3D7 strain culture was
tightly synchronized (sorbitol lysis on day 1, 70% Percoll® fol-
lowed after 2 h by sorbitol on day 4, sorbitol on day 6), and
after a further 40 h a final 70% Percoll® treatment was done.
Purified late stages were cultured in 10 mL of complete RPMI
without adding fresh RBCs, and when the majority of parasites
were segmented schizonts, E-64 protease inhibitor was added
to a final concentration of 10 µM. Between 6 to 10 h later, the
culture was centrifuged at 730g for 8 min and the pelleted cells
were taken up in 20 mL of PBS. The suspension was passed
sequentially through a 18G needle and a 1.2 µm filter
(Sartorius Stedim® Minisart) blocked for 30 min with PBS/1%
BSA. Merozoites in PBS were collected in a 50 mL Falcon tube
previously blocked for 1 h with PBS/1% BSA, and finally centri-
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fuged at 2200g for 10 min. The supernatant was removed
leaving about 200 µL of a merozoite suspension in PBS, which
was immediately used for targeting analysis.
For growth inhibition assays, P. falciparum 3D7 cultures
were adjusted to 3% hematocrit and 1.5% parasitemia with
more than 90% of parasites at ring stage after sorbitol synchro-
nization. 75 μL of these Plasmodium cultures were plated in
96-well plates and incubated for 40 h at 37 °C in the presence
of free drugs and dendrimer–drug conjugates (added in a
volume of 75 μL). After addition of 0.5 µM Syto-11 (Thermo
Fisher Scientific, Inc.), parasitemia was determined by flow
cytometry as previously described.28
Cytotoxicity and hemolysis assays
Human umbilical vein endothelial cells (HUVEC, ATCC) were
cultured in Medium 199 (M199, LabClinics) supplemented
with 10% heat-inactivated foetal bovine serum (FBS, PAA
Laboratories, Germany), 1% each penicillin/streptomycin
(Biological Industries), and 10 mM glutamine (complete
M199). 5000 cells per well were plated in 96-well plates
(Thermo Fisher Scientific Inc.) and after 24 h at 37 °C in 5%
CO2 atmosphere the medium was substituted by dilutions of
the dendrimers in 100 μL of culture medium without FBS, and
incubation was resumed for 48 h. 10 μL of 4-[3-(4-iodophenyl)-
2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate
labeling reagent (WST-1, Roche Diagnostics GmbH) was added
to each well, and the plate was incubated in the same con-
ditions for a further 3 h. After thoroughly mixing for 1 min on
a shaker, the absorbance of the samples was measured at
440 nm using a Benchmark Plus microplate reader (Bio-Rad
Laboratories Inc.). WST-1 in the absence of cells was used as
blank and samples were prepared in triplicate for each experi-
ment, including positive (10% bleach) and negative (PBS)
controls.
For hemolysis assays, human blood collected in citrate-
phosphate-dextrose buffer was washed as described pre-
viously.28 After the last washing step RBCs were diluted in PBS
to yield a solution with 6% hematrocrit. 100 μL of RBCs from
this suspension and 100 μL of a dendrimer sample were added
to a 96-well plate. Each assay was performed in triplicate,
including positive (1% Triton X-100) and negative (PBS) con-
trols. After incubating for 3 h at 37 °C in 90% N2, 5% CO2, and
5% O2, samples were collected in eppendorf tubes, spun at
16 000g for 5 min, and the supernatant absorbance was finally
measured at 541 nm.
Cell targeting analysis
400 µL of desynchronized living P. falciparum 3D7 cultures
were stained for 30 min with 4 μg mL−1 of the DNA dye
Hoechst 33342. HUVEC (1.5 × 104 cells per cm2) were treated
equally but for the use of complete M199 as culture medium,
and nuclei staining done at day 3 after plating (10 µg Hoechst
33342 per mL). After 3 washes with complete RPMI or M199,
respectively, Plasmodium cultures and HUVEC were incubated
in the presence of 0.15 mg mL−1 dendrimer conjugated to rho-
damine, for 90 min in the corresponding medium at 37 °C
with gentle stirring. Purified merozoites were incubated for
10 min at room temperature (RT) in the simultaneous pres-
ence of Hoechst 33342 and rhodamine-labeled dendrimers.
After washing with incomplete medium, nonfixed samples
were placed in a 8-well LabTek chamber slide system (Lab-
Tek®II, catalog number 155409) and the fluorescence of
Hoechst 33342, FITC and rhodamine (λex/em: 350/461, 488/520
and 553/627 nm, respectively) was observed with an IX51
inverted fluorescence microscope (Olympus). Confocal fluo-
rescence microscopy analysis was done with a Leica TCS SP5
laser scanning confocal microscope equipped with a DMI6000
inverted microscope, blue diode (405 nm), Argon (458/476/488/
496/514 nm), diode pumped solid state (561 nm) and Helium–
Neon (594/633 nm) lasers and PLAN APO 63× oil (NA 1.4)
immersion objective lens. For flow cytometry analysis,
Plasmodium cultures were diluted in PBS to a final concen-
tration of 1–10 × 106 cells per mL, and samples were analyzed
using a LSRFortessa™ flow cytometer instrument (BD
Biosciences) set up with the 5 lasers, 20 parameters standard
configuration. The single-cell population was selected on a
forward-side scatter scattergram. Rhodamine was excited using
a yellow-green laser (561 nm), and its fluorescence collected
through a 582/15 nm filter. Hoechst 33342 was excited with a
violet laser (405 nm), and its fluorescence collected using a
450/40 nm filter.
Determination of the maximum tolerated dose (MTD) in mice
Seven week-old inbred BALB/cAnR mouse females (18–20 g,
Janvier Laboratories) were maintained under standard environ-
mental conditions (20–24 °C and 12 h/12 h light/dark cycle)
with ad libitum access to food and water. To ensure adminis-
tration and minimize injection stress, the animals were
anesthetized with isoflurane (4% for induction and 2.5% for
maintenance) in an oxygen stream, while a 250 µL bolus was
administered intravenously. To reduce the number of animals
used, an adaptation of OECD 425 Test Guideline was followed,
which consisted of a single ordered dose progression. The first
mouse received the dose initially planned for antimalarial
activity assays (see below), and the dose for the next animal
was either increased or decreased by a factor of 3.2 depending
on whether the first animal survived or died, respectively. Each
mouse was injected and evaluated for at least 48 h before the
next animal was treated. All animals were observed for toxic
signs during 14 days after dose injection. Following this proto-
col, three different concentrations of the dendrimers (11.7,
37.5 and 120 mg kg−1) were evaluated, prepared in PBS from a
50 mg mL−1 stock solution of dendrimers in sterile ddH2O. In
the presence of toxic effects including, among others, >20%
reduction in animal weight, aggressive and unexpected animal
behavior or the presence of blood in faeces, animals were
immediately anesthetized using a 100 mg kg−1 Ketolar plus
5 mg kg−1 Midazolan mixture and sacrificed by cervical dis-
location. Dendrimer MTD was therefore defined upon com-
pletion of the assay as the highest dosage exhibiting an
absence of the aforesaid toxicity signs. The animal care and
use protocols followed adhered to the specific national and
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international guidelines specified in the Spanish Royal Decree
53/2013, which is based on the European regulation 2010/63/
UE. The studies reported here were performed under protocols
reviewed and approved by the Ethical Committee on Clinical
Research from the Hospital Clínic de Barcelona (Reg. HCB/
2014/0910).
Antimalarial activity assay in vivo and dot-blot assays
The in vivo antimalarial activity of free CQ and of dendrimer-
CQ conjugates was analyzed in a 4-day blood suppressive test
as previously described.31 Briefly, BALB/c mice were inocu-
lated intraperitoneally with 2 × 106 RBCs from Plasmodium
yoelii yoelii 17XL (PyL) MRA-267-infected mice. Treatment
started 4 h later (day 0) with a single dose of 1.9 mg CQ per
kg per day administered intravenously as diphosphate–drug
or dendrimer–drug, followed by identical dose adminis-
tration for the next 3 days. Tested compounds were prepared
in PBS and the control groups received PBS. Parasitemia was
monitored daily by microscopic examination of Giemsa-
stained thin blood smears using the Plasmoscore 1.3 soft-
ware (Burnet Institute, Melbourne, Australia). When all sur-
viving animals had completely cleared Plasmodium infection
they were re-infected (on day 69) with P. yoelii yoelii 17XL
(PyL) MRA-267 as above and left untreated. Survival was
monitored until day 90, when blood samples (400 µL) were
collected on 10 µL of 10% EDTA, centrifuged for 5 min
(470g), and the obtained plasma supernatants were stored at
−20 °C. 3 µL of P. yoelii yoelii 17XL (PyL) MRA-267 extracts32
containing 1.5 µg protein were applied and allowed to dry on
a nitrocellulose membrane (0.45 µm, Bio-Rad, catalog
number 1620145). Non-specific sites were blocked with 5%
BSA in TBS-T (0.05% Tween 20, 150 mM NaCl, 20 mM Tris-
HCl, pH 7.5) for 1 h at RT. Then the membrane was first
incubated (30 min, RT) with the plasma supernatants dis-
solved in TBS-T (1 : 5000 dilution), washed (TBS-T, 3 ×
5 min), and then treated with a secondary goat anti-mouse
antibody conjugated to horseradish peroxidase (Millipore) in
TBS-T (1 : 10 000 dilution; 30 min, RT), followed by 3 × 5 min
washes with TBS-T and one wash with TBS (TBS-T without
Tween). Finally the membrane was incubated with ECL
Prime Western Blotting Detection Reagent (Luminol,
Amersham) for 30–60 s and scanned (ImageQuant LAS4000,
GE Healthcare).
Statistical analysis
Data are presented as the mean ± standard error of at least
three independent experiments, and the corresponding stan-
dard errors in histograms and graphs are represented by error
bars. Percentages of viability were obtained using non-treated
cells as control of survival and IC50 values were calculated by
nonlinear regression with an inhibitory dose–response model
using GraphPad Prism5 software. Concentrations were trans-
formed using natural log for linear regression. Regression
models were adjusted for replicates and assay data.
Results and discussion
Preparation and characterization of the nanocarriers
Synthesis and characterization of HDLDBC-bGMPA.
HDLDBC-bGMPA was synthesized for the first time for this
study by CuAAC of the bis(alkyne) derivative of Pluronic® F127
and two t-Boc protected amino-terminated bis-GMPA dendrons
(Fig. 2A and ESI†). The t-Boc-protected bis-GMPA dendron of
3rd generation with an azide group at the focal point and eight
terminal amino groups was synthesized as previously
described by us.24 The synthesis of the alkyne functionalized
Pluronic® was carried out by esterification of Pluronic® F127
with 4-(prop-2-ynyloxy)benzoic acid as we reported pre-
viously.18 The CuAAC reaction was performed in DMF at 45 °C
under argon atmosphere during 2 days. The Cu(I) catalytic
species was formed “in situ” by reduction of Cu(II) salt with (L)-
ascorbate while TBTA was added to increase its stability. An
excess of dendron (1.3 mole of dendron per 1.0 mole of alkyne
group) was used to obtain a complete functionalization of the
linear polymer. The t-Boc protecting groups were removed
from the dendrons in acidic conditions with HCl in ethyl
acetate and the final product was obtained with a moderate
yield of 61%.
The correct grafting of the two bis-GMPA dendrons at the
extremities of Pluronic® F-127 was first controlled by 1H
(Fig. 2B) and 13C (Fig. 2C) NMR experiments (see Fig. S1.1,
S1.2 and S1.3† for 1H–1H COSY and full 1H and 13C NMR
spectra). The appearance of a peak at 8.19 ppm (H-15) in the
1H NMR spectrum and two peaks at 125.8 (C-15) and
140.4 ppm (C-14) in the 13C NMR spectrum confirmed the for-
mation of the triazole rings. Additionally, three other signals
were shifted downfield in the 1H NMR spectra of the final
HDLDBC when compared with the spectra of its two precur-
sors. Thus, the signal corresponding to the methylene protons
in the α-position of the triazole rings belonging to the linear
polymeric part (H-13) was shifted from 4.72 to 5.30 ppm. The
signals corresponding to the methylene protons in the α- and
β-positions of the triazole rings belonging to the dendritic part
(H-16 and H-17) were shifted from 3.20 and 1.65 to 4.45 and
1.95 ppm, respectively. Moreover, the relative integrations of
the signals corresponding to the dendrons and linear polymer
corroborated the grafting of two dendrons at the terminal posi-
tion of the Pluronic® F-127 (Table S1.1†).
The characteristic bands of the bis-GMPA dendrons and
Pluronic® F-127 could be observed in the FTIR spectrum,
(Fig. 2D). First, the presence of the poly(ether) Pluronic® F-127
was asserted by the intense band at 1101 cm−1 (C–O bond
vibration stretching) and the two intense bands at 2881 and
1344 cm−1 (C–H bond vibrations). Second, the presence of the
poly(ester amide) bis-GMPA dendrons was confirmed by the
two bands at 1755 and 1664 cm−1 corresponding to CvO
bond vibration stretching of ester and amide groups,
respectively.
SEC was performed with the t-Boc-protected precursor of
HDLDBC-bGMPA due to its low solubility in the elution
solvent employed for chromatography, i.e. THF (Fig. 2E). Two
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peaks were observed in the chromatograms of both, the com-
mercial Pluronic® F-127 and the HDLDBC, showing the poly-
dispersity of these compounds. The correct functionalization
of Pluronic® was nevertheless asserted as both peaks corres-
ponding to it showed lower retention time than the two peaks
corresponding to the starting Pluronic® F-127. Additionally,
no peak corresponding to residual free bis-GMPA dendron
could be observed. In summary, all experimental data
obtained during the characterization of HDLDBC-bGMPA con-
firmed the correct insertion of two bis-GMPA dendrons at each
extremity of the linear polymer and the absence of unreacted
free linear polymer or dendron.
Structural studies. The ability of HDLDBC-bGMPA to self-
assemble in water forming micellar nanocarriers was con-
firmed by CMC determination using the Nile Red method
(Fig. 3A). The fluorescence intensity of this solvatochromic
fluorophore increases drastically when it migrates into and is
retained within the lipophilic part of aggregates formed by the
self-assembly of amphiphilic molecules.26 Thus, a CMC of
1.0 mg mL−1 for HDLDBC-bGMPA was determined, which was
consistent with the formation of micelles in which the lipophi-
lic core of the central linear Pluronic® block copolymer is sur-
rounded by hydrophilic ammonium terminated dendrons.
Rounded structures were observed in AFM and negatively
stained TEM images of HDLDBC-bGMPA. The average dia-
meter calculated from TEM micrographs was 13 ± 3 nm, con-
sistent with the height of the structures determined in water
by AFM (Fig. 3B and C), and with the average in number value
measured by DLS, 26 ± 6 nm (Fig. S2.1.A†).
The morphology of two globular dendronized hyper-
branched polymers, DHP-bMPA, was also analyzed by TEM
and AFM (Fig. 3D–F). The two generations tested (n = 3 and n =
4 in Fig. 1B) appeared as rounded objects, with average dia-
meters calculated from TEM images of 9.8 ± 2.7 nm and 13.5 ±
3.5 nm, respectively. These dimensions are consistent with the
expected formation by these dendronized hyperbranched poly-
mers of unimolecular micelles well dispersed in aqueous solu-
tion.33,34 DLS measurements of DHP-bMPA (n = 4) gave a dia-
meter of 11 ± 2 nm (Fig. S S2.1.B†). As for HDLDBC-bGMPA
carriers, the size of DHP-bMPA unimolecular micelles results
a priori appropriate to enter into pRBCs.21
Unspecific toxicity and hemolysis assays. None of the den-
dritic derivatives was cytotoxic or hemolytic up to a concen-
tration of 0.15 mg mL−1 (Fig. 3G and H), which is 10 times
higher than the highest amount to be used later for in vitro
growth inhibition assays, and 8 times higher than the daily
dose to be used later for in vivo assays.
In vitro targeting analysis
Rhodamine labeling of the nanocarriers. In order to explore
the targeting behavior of the nanocarriers towards pRBCs,
DHP-bMPA-Rho (Fig. 4A), a DHP-bMPA covalently labeled with
an average of seven rhodamine B moieties per macromolecule,
was prepared as previously described.25 HDLDBC-bGMPA
nanocarriers were labeled by encapsulating a lipophilic modi-
fied rhodamine B (Rho(C17)2) red fluorophore, using the oil-
in-water procedure as previously reported by us.27 In order to
check the stability of this labeling, Rho(C17)2 release from the
HDLDBC-bGMPA/Rho(C17)2 conjugates was studied by dialy-
sis. Unmodified water-soluble rhodamine B fluorophore was
encapsulated within HDLDBC-bGMPA micelles following the
same protocol, to be used as a control. The resulting release
profiles showed that whereas 50% of the encapsulated rhoda-
mine B is released during the first 2 h, Rho(C17)2 is kept
encapsulated throughout the 72 h of the experiment (Fig. 4B).
Erythrocyte targeting analysis. Fluorescence microscopy ana-
lysis of non-fixed samples (Fig. 5A) showed that whereas
HDLDBC-bGMPA was incorporated by all RBCs, DHP-bMPA
exhibited at the same concentration a clear targeting speci-
ficity for pRBCs. Higher-resolution confocal fluorescence
microscopy images of DHP-bMPA-containing samples revealed
that the polymer fluorescence was associated to the pRBC
plasma membrane and to intraerythrocytic parasites (Fig. 5B).
In the latter case fluorescence was not detected in the RBC
cytosol and was circumscribed by the plasma membrane of
Plasmodium. These observations suggested a specific binding
of DHP-bMPA to Plasmodium falciparum antigens.
Fig. 3 Characterization of nanocarriers. Nile Red fluorescence intensity
as a function of HDLDBC-bGMPA concentration (A), TEM image (B) and
AFM image in water on mica surface (C) of HDLDBC-bGMPA, TEM
images of DHP-bMPA (n = 3 and n = 4 in Fig. 1B; D and E, respectively),
and AFM image of DHP-bMPA (n = 4 in Fig. 1B) in water on mica surface
(F). Cytotoxicity (G) and hemolysis assay (H) of the largest DHP-bMPA (n
= 4 in Fig. 1B) and HDLDBC-bGMPA.
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The differential RBC targeting of DHP-bMPA and HDLDBC-
bGMPA was confirmed by flow cytometry assays (Fig. 6);
whereas HDLDBC-bGMPA associated with P. falciparum mero-
zoites and with both parasitized and non-parasitized erythro-
cytes, DHP-bMPA interacted only with merozoites and with
pRBCs. HDLDBC-bGMPA interaction with both RBCs and
pRBCs does not invalidate it as a potential carrier of antima-
larial drugs in targeted delivery strategies. As we have shown
before, delivering antimalarial compounds to non-infected
erythrocytes might represent an interesting therapeutic
approach whereby Plasmodium would encounter a hostile
environment since the very first moment after RBC inva-
Fig. 4 Rhodamine labeling of the nanocarriers. Chemical structure of the covalently labeled DHP-bMPA-Rho derivative (A), and release profile of
the fluorescent rhodamine labels, Rho(C17)2 and Rho, from the nanocarrier HDLDBC-bGMPA (B).
Fig. 5 Fluorescence microscopy cell targeting analysis of rhodamine-
labeled DHP-bMPA and HDLDBC-bGMPA to non-fixed RBCs and
pRBCs. (A) Conventional fluorescence microscopy cell targeting of both
polymers. (B) Confocal fluorescence microscopy cellular and subcellular
targeting of DHP-bMPA-Rho.
Fig. 6 Flow cytometry analysis of the targeting of rhodamine-labeled
DHP-bMPA and HDLDBC-bGMPA to RBCs, pRBCs and merozoites (the
latter two represented in blue, upper left areas; their DNA is stained by
Hoechst 33342). pRBCs and merozoites positive for rhodamine are
shown in purple (upper right areas) whereas orange (lower right areas)
indicates cells or cell debris (the latter only in merozoite samples)
lacking DNA that are associated to the polymers. Percentages indicate
the fraction of rhodamine-positive counts relative to the total number of
recorded cells or particles in each sample. Arrowheads indicate ring
stages.
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sion.35,36 This scenario resulted in a significantly improved
efficacy of drugs encapsulated inside liposomes targeted to
both pRBCs and to non-parasitized red blood cells.35,37
The modest binding of DHP-bMPA to early ring forms,
where the parasite has not significantly modified the erythro-
cyte membrane, suggests that this polymer might interact pre-
dominantly with exported Plasmodium antigens, which are
scarce in rings and completely absent from non-parasitized
RBCs.
Endothelial cell targeting analysis. Other cell types besides
RBCs will be exposed to targeted polymers used as drug car-
riers in the blood stream, mainly leukocytes and blood vessel
endothelium. Of these, leukocytes are in numbers several
orders of magnitude below those of RBCs, but endothelial
cells are sufficiently abundant to compete with pRBCs for
nanocarrier intake. We have shown above that, at the polymer
concentrations used in this work, endothelial cells do not
experience significant cytotoxic effects. However, they might
contribute to the clearance from the blood of a significant
amount of polymers, thus reducing the efficacy of nanovector
preparations. When endothelial cell uptake of the polymers
was analyzed by fluorescence microscopy, it was observed that
both DHP-bMPA and HDLDBC-bGMPA were incorporated by
HUVEC cells. However, whereas HDLDBC-bGMPA had a cyto-
solic localization, the subcellular targeting of DHP-bMPA was
found to be exclusively nuclear (Fig. 7). This result offers inter-
esting perspectives for the use of this type of polymers in the
targeting to cell types other than erythrocytes and to different
subcellular locations. Nevertheless, the observed interaction of
both polymers with the endothelial lining has to be taken into
account in future pharmacokinetic studies regarding potential
applications as drug carriers against the blood stages of
malaria.
In vitro antimalarial activity of drug-loaded nanocarriers
Drug encapsulation. CQ, PQ and QN were encapsulated
within DHP-bMPA and HDLDBC-bGMPA nanocarriers. Except
where otherwise indicated, the DHP-bMPA structure used here-
after in this work will be n = 4. The encapsulation was per-
formed following the oil-in-water method at feeding ratios of
1 : 0.5 (wDHP/wdrug) and 1 : 1 (wHDLDBC/wdrug), respectively. This
procedure allowed to encapsulate all three antimalarial drugs
in DHP-bMPA nanocarriers with drug loading contents around
20% in weight and good encapsulation efficiencies, ranging
from 37% to 60% (Table 1). A smaller DHP-bMPA (n = 3 in
Fig. 1B) was also used to encapsulate all three antimalarials,
obtaining similar drug contents and loading efficiencies
(Table S2.1†). As for the HDLDBC-bGMPA carrier, higher
loading capacities, between 30% and 48% in weight, and
rather good encapsulation efficiencies, ranging from 31% to
48%, were attained.
All the aqueous solutions obtained after the encapsulation
procedure were freeze-dried in order to enhance stability
during storage of the carrier/drug systems. The effective encap-
sulation of drugs was asserted by comparing the absorption
spectra of the drugs in water with those of the re-dissolved
carrier/drug freeze-dried conjugates (Fig. S2.3 and S2.4†). In all
cases, the differences observed reflect interactions between
nanocarriers and drugs.
TEM images of drug-containing nanocarriers showed in all
cases homogeneous dispersions of rounded objects (Fig. 8),
the diameters of which were similar to those of empty nano-
carriers, and always ≤20 nm (Table 1). This small size should
favor their entry in pRBCs, since Plasmodium induces new per-
meation pathways that confer to the host cell an increased per-
meability to a wide range of particles up to diameters of
50–70 nm.21 Whereas the unimolecular micelles formed by
DHP-bMPA in water (Fig. 8A) had an average diameter around
13.5 nm, DHP-bMPA/drug systems had an average diameter
between 12 and 20 nm. Likewise, the loading of antimalarial
drugs within HDLDBC-bGMPA nanocarriers resulted in struc-
tures with average sizes ranging from 11 to 17 nm (Fig. 8B),
whereas the empty nanocarrier had an average size around
13 nm. AFM observation of both CQ-loaded carriers confirmed
the formation of these rounded objects (Fig. 8).
In vitro antimalarial activity assays. When the corres-
ponding formulations of HDLDBC-bGMPA and DHP-bMPA
Fig. 7 Fluorescence microscopy cell targeting analysis of rhodamine-
labeled DHP-bMPA and HDLDBC-bGMPA to HUVEC cells.
Table 1 Encapsulation of CQ, PQ and QN in HDLDBC-bGMPA and
DHP-bMPA nanocarriers and average diameters of the carrier/drug
systems determined by TEM
Drug
mg drug/mg
carrier EEa (%)
Average
diameter (nm)
Empty 13 ± 3
HDLDBC-bGMPA CQ 0.307 31 17 ± 3
PQ 0.408 41 11 ± 2
QN 0.475 48 14 ± 6
Empty 13.5 ± 3.5
DHP-bMPA CQ 0.246 60 20 ± 7
PQ 0.214 60 19 ± 8
QN 0.229 37 12 ± 3
a Encapsulation efficiency (EE, %) represents the fraction of encapsu-
lated drug relative to the quantity used to perform the encapsulation.
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conjugated with CQ, PQ and QN were tested in growth inhi-
bition assays of P. falciparum in vitro cultures, the encapsu-
lated drugs had IC50 values comparable to those of the free
compounds (Fig. 9), indicating an adequate release of the
drugs from the polymers. However, the good targeting of
the nanostructures towards pRBCs offered prospects for a
better performance of the encapsulated drugs, suggesting
that part of the nanoparticle-conjugated compounds might
not be adequately released. To explore this possibility, the
release dynamics against PBS of CQ encapsulated within
HDLDBC-bGMPA and DHP-bMPA was analyzed during three
days (Fig. 10). As already described for other dendritic
derivatives,18 CQ was progressively released from both
nanocarriers in a process that reached completion in about
24 h; after this time, about 35% of CQ remained stably
encapsulated. Modifications of the polymer architecture or
chemistry to endow it with more porosity or less affinity for
the drugs might contribute to an improved drug release
profile.
In vivo antimalarial activity of CQ-loaded nanocarriers
MTD assays indicated that DHP-bMPA and HDLDBC-bGMPA
could be safely administered to mice without evident signs of
animal distress up to respective doses of at least 37.5 and
120 mg kg−1. For the evaluation of the formulations in an
in vivo model of malaria, we selected CQ because, being the
in vitro performance of its encapsulated form vs. the free com-
pound similar to that of PQ and QN, this drug had been suc-
Fig. 8 Negatively stained TEM images of the drug-loaded nanocarriers
HDLDBC-bGMPA (A) and DHP-bMPA (B). Insets show AFM images of the
corresponding CQ-loaded nanocarriers.
Fig. 9 Growth inhibition assays of P. falciparum in vitro cultures treated
with CQ, PQ and QN, either free or encapsulated in HDLDBC-bGMPA
and DHP-bMPA. In parentheses are indicated the corresponding IC50
values.
Fig. 10 Release profiles of CQ from the dendrimers DHP-bMPA and
HDLDBC-bGMPA at 37 °C.
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cessfully tested in our group as part of different polymeric and
liposomal encapsulations.18,35,38 When polymer-CQ conjugates
were administered intravenously (1.9 mg CQ per kg per day for
4 consecutive days) to mice infected with the lethal murine
malaria parasite P. yoelii yoelii 17XL (PyL) MRA-267, DHP-
bMPA-CQ did not improve survival significantly, but animals
treated with HDLDBC-bGMPA-CQ survived much longer (3 out
of 5 mice lived ≥20 days) than untreated controls, which typi-
cally died at day 6 (Fig. 11A and C). One mouse treated with
HDLDBC-bGMPA-CQ was actually cured and, when re-infected
at day 69 and left untreated, it recovered completely without
showing any symptoms of malaria or developing parasitemia
above the detection level of microscopy examination. The
detection in the plasma of this cured animal of antibodies
against P. yoelii antigens (Fig. 11B) was consistent with the
development of immunity against the disease. Free CQ-treated
controls which were administered the same drug concen-
tration were cured in 4 out of 5 animals, which became also
resistant to re-infection. Although HDLDBC-bGMPA-encapsu-
lated CQ did not improve the efficacy of such a good drug as
CQ, the strategy presented here can be adapted to the targeted
drug delivery of other antimalarials, already existing or yet to
be discovered.
In vivo, HDLDBC-bGMPA-CQ worked better than DHP-
bMPA-CQ, possibly because the former targets all RBCs. The
loading of antimalarial drugs into non-parasitized red blood
cells has been described as an efficient approach to signifi-
cantly reduce parasite survival,35,36 as long as neither nano-
carriers nor drugs affect the natural role of erythrocytes as O2
and CO2 transporters. Both dendrimeric structures studied in
this work lack significant in vitro cytotoxicity and hemolytic
activity, suggesting that they will not interfere with the red
blood cell physiology. HDLDBC-bGMPA then holds promise
for the development of innovative antimalarial prophylactic
strategies at the cell level whereby Plasmodium would be
exposed to drugs since the very first moment after invading a
host cell.
The modest in vivo efficacy of the encapsulated formu-
lations relative to the free drug is, in part, likely resulting from
renal and splenic clearance of the nanoparticles, in addition
to their endothelial cell uptake. Nanoparticles must be larger
than 20 nm in diameter to avoid filtration by the kidney,39 and
smaller than 100 nm to avoid a specific sequestration by sinu-
soids in spleen and fenestra of liver, which are approximately
150–200 nm in diameter.40 Therefore, systemically adminis-
tered nanoparticles should have diameters from 20 to
100 nm,41 and overall, literature suggests that nanoparticles in
the 50–100 nm size range display the lowest blood clearance
rates.42 Since the average diameter of the dendrimeric nano-
particles used here is just below 20 nm, increasing their size to
ca. 50 nm might provide an improved pharmacokinetics and
better in vivo performance.
In addition, upon intravenous administration of nano-
particles, these are coated by a variety of serum proteins which
are recognized by the scavenger receptor on macrophage cell
surfaces and internalized, leading to a significant loss of nano-
particles from the circulation.43 The serum proteins binding
on the nanoparticles are also termed “opsonins”, and the
macrophages contributing the major loss of injected dose are
also known as the reticuloendothelial system or mononuclear
phagocyte system. Reducing protein binding is the key point
for developing a long-circulation nanoparticle formulation. To
minimize opsonization, the most commonly used strategy is to
conjugate onto the surface of the nanoparticles the polyethyl-
ene glycol polymer44 or polyoxazolines,45 both hydrophilic
polymers that provide good steric hindrance for preventing
protein binding.
Finally, in addition to expanding blood residence time
and reducing unspecific interactions with non-target cells
and tissues, a faster targeting dynamics can be conferred to
the nanoparticles by coating them with molecules binding
pRBCs with certain degree of specificity, as it has been
described for heparin.46,47 Here we have shown that
although DHP-bMPA exhibited a remarkable preferential
binding to pRBCs vs. RBCs, about 40% of pRBCs interacted
with this polymer similarly as a fraction of the non-infected
erythrocyte population did (Fig. 6). The functionalization of
DHP-bMPA-Rho with up to 15% heparin-FITC (w/w) did not
affect the targeting specificity of the polymer towards pRBCs
(Fig. S3.1†), and it actually favored specific interactions with
pRBCs vs. RBCs (data not shown). The known activity of
Fig. 11 Four-day blood suppressive antimalarial activity assay of free
CQ and of carrier-CQ conjugates. (A) Kaplan–Meier plot of the survival
of P. yoelii yoelii 17XL (PyL) MRA-267-infected mice treated with 1.9 mg
CQ per kg per day for 4 consecutive days, administered intravenously as
diphosphate–drug or dendrimer–drug. When all surviving animals had
completely cleared Plasmodium infection they were re-infected (on day
69) with P. yoelii and left untreated. (B) Dot blot for the detection at day
90 in the plasma of surviving animals of antibodies against P. yoelii. The
negative control was processed substituting PBS for plasma. (C)
Parasitemia counts of the different mouse groups until animal death or
parasite clearance.
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heparin as targeting element of liposomes47 suggests that
its presence on the nanocarrier increased the number of
polymers bound to each pRBC. Last but not least, since
heparin has antimalarial activity, this result indicates that it
can be a constituent of pRBC-targeted multicomponent
nanoparticles carrying different types of antimalarial
agents.
Conclusions
To eradicate malaria, there is an urgent need for the combi-
nation of different strategies working together, because it is
unlikely for a single approach to be capable of success. It is
important to emphasize the importance of implementing in
advance efficient methods of antimalarial drug encapsulation
and targeted delivery in order to make a good use of future
therapeutic compounds. This should result in a more rational
administration regime that could contribute to expand the
time during which drugs can be used before resistance
evolves. In addition, such strategy might widen the number of
chemicals that reach the clinic if eventual unspecific toxicities
can be reduced through a targeted delivery approach. The
resulting lower overall doses should not trigger pernicious
side-effects in the patient while keeping high local doses on
the parasite in order to quickly eliminate all the cells of the
pathogen, thus reducing the evolution of resistances. Here, we
have described micellar carriers based on dendritic macro-
molecules containing bis-MPA and glycine that hold promise
for the development of future antimalarial nanomedicines tar-
geted to both Plasmodium-infected and non-infected
erythrocytes.
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